Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Peter Kwong and John Mascola.
Connection Strength

4.604
  1. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. Immunity. 2018 05 15; 48(5):855-871.
    View in: PubMed
    Score: 0.768
  2. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. J Biol Chem. 2021 10; 297(4):101127.
    View in: PubMed
    Score: 0.241
  3. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines (Basel). 2021 Jan 21; 9(2).
    View in: PubMed
    Score: 0.231
  4. Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host Microbe. 2020 12 09; 28(6):867-879.e5.
    View in: PubMed
    Score: 0.228
  5. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci Rep. 2020 10 23; 10(1):18149.
    View in: PubMed
    Score: 0.227
  6. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020 10 27; 33(4):108322.
    View in: PubMed
    Score: 0.227
  7. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. Proc Natl Acad Sci U S A. 2018 11 27; 115(48):12265-12270.
    View in: PubMed
    Score: 0.199
  8. Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. ACS Infect Dis. 2018 05 11; 4(5):788-796.
    View in: PubMed
    Score: 0.189
  9. Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Rep. 2018 02 13; 22(7):1798-1809.
    View in: PubMed
    Score: 0.189
  10. Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. Cell Rep. 2017 Dec 05; 21(10):2992-3002.
    View in: PubMed
    Score: 0.186
  11. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 2017 Oct; 13(10):1115-1122.
    View in: PubMed
    Score: 0.182
  12. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. J Virol. 2017 05 15; 91(10).
    View in: PubMed
    Score: 0.179
  13. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep. 2017 04 25; 19(4):719-732.
    View in: PubMed
    Score: 0.178
  14. Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. Immunol Rev. 2017 01; 275(1):108-128.
    View in: PubMed
    Score: 0.175
  15. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
    View in: PubMed
    Score: 0.060
  16. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 08 05; 184(16):4203-4219.e32.
    View in: PubMed
    Score: 0.059
  17. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 05; 593(7857):130-135.
    View in: PubMed
    Score: 0.058
  18. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host Microbe. 2020 12 09; 28(6):880-891.e8.
    View in: PubMed
    Score: 0.057
  19. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
    View in: PubMed
    Score: 0.056
  20. Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. Sci Rep. 2019 10 11; 9(1):14696.
    View in: PubMed
    Score: 0.053
  21. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 2019 10; 6(10):e667-e679.
    View in: PubMed
    Score: 0.052
  22. Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat Immunol. 2019 Jun; 20(6):765.
    View in: PubMed
    Score: 0.052
  23. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun. 2018 10 08; 9(1):4136.
    View in: PubMed
    Score: 0.049
  24. Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. PLoS Pathog. 2018 07; 14(7):e1007159.
    View in: PubMed
    Score: 0.048
  25. Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. Cell Host Microbe. 2018 06 13; 23(6):832-844.e6.
    View in: PubMed
    Score: 0.048
  26. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018 05 15; 92(10).
    View in: PubMed
    Score: 0.048
  27. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS One. 2018; 13(3):e0193773.
    View in: PubMed
    Score: 0.047
  28. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Rep. 2017 12 26; 21(13):3681-3690.
    View in: PubMed
    Score: 0.047
  29. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017 10 06; 358(6359):85-90.
    View in: PubMed
    Score: 0.046
  30. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406).
    View in: PubMed
    Score: 0.046
  31. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Proc Natl Acad Sci U S A. 2017 08 08; 114(32):8614-8619.
    View in: PubMed
    Score: 0.045
  32. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol. 2017 Jul 14; 2(13).
    View in: PubMed
    Score: 0.045
  33. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity. 2017 05 16; 46(5):777-791.e10.
    View in: PubMed
    Score: 0.045
  34. Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation. Front Immunol. 2017; 8:537.
    View in: PubMed
    Score: 0.045
  35. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
    View in: PubMed
    Score: 0.044
  36. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0.044
  37. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog. 2017 01; 13(1):e1006148.
    View in: PubMed
    Score: 0.044
  38. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015 Jul 28; 6:7712.
    View in: PubMed
    Score: 0.040
  39. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 2009 May; 5(5):e1000445.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.